our products

UriMoni

Real-time

Continuous on-site urine monitoring for improved diagnosis and treatment monitoring.

Urimoni - RT

Continuous urine monitoring solutions for realtime results

Specifically designed for bedside use in intensive care settings, this state-of-the-art device is poised to transform the way biomarkers in urine are measured, enhancing patient care, reducing workload, and improving outcomes.

Continuous monitoring

With real-time bedside testing capabilities, UriMoni - RT empowers healthcare teams with immediate access to crucial patient data. Rapid measurement of biomarkers allows for timely interventions and the ability to closely monitor a patient's condition, enabling swift adjustments to treatment plans and more effective treatment.

Uncompromising Precision

UriMoni RT utilizes advanced sensor technology to provide unparalleled precision in detecting and quantifying vital biomarkers in urine. This accuracy ensures that healthcare professionals can make informed decisions promptly, leading to more targeted treatments and optimized patient care.

Enhanced Kidney Function Monitoring

UriMoni RT plays a pivotal role in bedside monitoring of kidney function. By continuously measuring specific biomarkers in urine, healthcare professionals can gain valuable insights into renal health and identify early signs of kidney dysfunction (such as Acute Kidney Injury). This allows for early diagnosis and proactive interventions, helping to prevent further complications and improve patient outcomes right at the bedside.

use cases

Clinical need for on-site urine monitoring

There is a broad unmet need for clinical urine monitoring on the spot. Applications range from continuous monitoring by connecting UriMoni to a catether to Point-of-Care measurements in a hospital or GP clinic.

The proprietary UriMoni technology can facilitate all demands for on-site urine monitoring. With our current products we focus on two use cases:

Monitoring of kidney function to assess the risk of developing Acute Kidney Injury (AKI).
Monitoring ion concentration to allow for natriuresis-guided therapy in Acute Heart Failure (AHF).

aki

Monitoring of kidney function to assess risk of Acute Kidney Injury

UriMoni enables in frequent urine monitoring for early detection of kidney damage and treatment response, by measuring creatinine, urea, K, and pH.

Natriuresis-guided diuretic therapy in Acute Heart Failure

UriMoni enables frequent urine monitoring for assessing diuretic response and early identification of kidney damage, by measuring ion concentration (Na, K, Mg) and creatinine, from patient urine.

Versatile and scalable

Seamless Data Integration

Although the UriMoni has a built in screen, our products allow for direct coupling with monitoring instrument hubs, as well as electronic health record (EHR) systems.

Streamlined Workflow

We have designed our products in such a way that their operation is minimally disruptive. Use of the UriMoni can easily be integrated into existing protocols and workflows.

Versatile and Scalable

Our products are designed using a modular approach. Do you want to measure something else? Get in touch!

Heart Failure Management

Beyond kidney function monitoring, our products supply important information that can assist in the management of heart failure using diuretics.

timeline

Where we are now

faq's

Frequently asked questions

What is the difference between the UriMoni - RT and UriMoni- POC

Currently, the biosensors in both products are identical. The difference is in the sampling method. UriMoni - POC is a point-of-care device where the samples are manually entered into the device. UriMoni - RT is connected to a catheter and allows continuous monitoring.

Which biomarkers can be measured with the UriMoni?

The current version of UriMoni contains biosensors for pH, conductivity (marker for ion content) and creatinine. Other biosensors are under development.

Can we participate in the clinical validation studies?

Yes! Paramedir is always open to new partnerships. We welcome clinical partners interested in joining the UMCG to test our technology in clinical settings.

When do you expect to receive regulatory approval?

Regulatory strategy is an integral part of our product development. It is integrated into everything we do in R&D. A technical file for regulatory approval is already being prepared. We expect to submit the technical file for UriMoni - POC in 2026. This will be the stepping stone for UriMoni - RT, which will follow in 2027.